Treatment is essential because HD chorea limits people’s lives1

The vast majority of patients with Huntington’s disease (HD) develop chorea (nearly 90%)2

Chorea can be one of the early signs of HD, and may cause significant functional impact.3

Patients may experience functional
impact on3:

Pen icon.

Fine and gross motor
functions

Person walking icon.

Gait and balance

Scale icon.

Ability to maintain weight


In a survey conducted by the Huntington’s Disease Society of America (HDSA) published in 2016, caregivers cited chorea as the most impactful symptom of HD3,4

As it progresses, movements become more frequent, and appear throughout the body, interfering with activities of daily life. When it does progress, patients become completely dependent on their
carepartners, and carepartners can become overwhelmed.1

By treating HD chorea early, you can make a difference in patients’ lives5

The HDSA recommends evaluating the need for anti-chorea therapy at least once a year6

  • In early Huntington’s disease, a 1-point change in Total Motor Score, which measures overall motor symptoms, is associated with an approximately 10% loss in likelihood of being able to work, manage finances, drive, and supervise children7,8
  • Most patients and carepartners state that it is “very important” to manage chorea, with the main reasons including loss of independence, unpredictability/
    uncontrollability, and impact on family life5

There are no data to suggest that AUSTEDO affects any of the outcomes presented above.


Management of chorea may be met with many challenges

There are a limited number of FDA-approved treatment options available for HD chorea.3,9

Limitations of tolerability3,9

  • Medications may have dose-limiting side effects. Treatment of chorea should be determined individually as a balance of chorea reduction and medication tolerability

Severity of chorea3

  • Chorea severity may vary over the course of the disease

Prevalence of depression and suicidality in HD

  • The lifetime prevalence of major depression in people with HD is about 40%6
  • Suicide rates range from approximately 5% to 13%10
  • 25% of patients attempt suicide11

Concomitant medications6

  • Some prescription medications may worsen voluntary motor control

Gray video icon

Watch as Eileen discusses how HD chorea has impacted her life, and in particular, her work

Gray video icon

REFERENCES: 1. Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40. 2. Data on file. North Wales, PA: Teva Neuroscience, Inc. 3. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington’s Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington’s Disease Society of America; 2014. 4. Simpson JA, Lovecky D, Kogan J, Vetter LA, Yohrling GJ. Survey of the Huntington’s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J Huntingtons Dis. 2016;5(4):395-403. 5. Thorley EM, Iyer RG, Wicks P, et al. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11(5):547-559. 6. Nance M, Paulsen J, Rosenblatt A, Wheelock V. 2011. A Physician’s Guide To The Management Of Huntington’s Disease. 3rd ed. New York: Huntington’s Disease Society of America. 7. Beglinger LJ, O’Rourke JJF, Wang C, Langbehn DR, Duff K, Paulsen JS; for the Huntington Study Group Investigators. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178(2):414-418. 8. Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597-603. 9. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 10. Wetzel HH, Gehl CR, Dellefave-Castillo L, et al. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;188(3):372-376. 11. Killoran A, Biglan KM. Current therapeutic options for Huntington’s disease: good clinical practice versus evidence-based approaches? Mov Disord. 2014;29(11):1404-1413.